Supervisors info:
Μπίμπας Αθανάσιος, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Σέγγας Ιωάννης, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Ηλιάδου Βασιλική, Αναπληρώτρια Καθηγήτρια, Ιατρική Σχολή, ΑΠΘ
Summary:
Introduction: In 1976, Yoshinori Kidani invented oxaliplatin. Since 1996, as a third-generation platinum agent has been an important drug in the field of anticancer therapy. Furthermore, in 2008, Auditory Neuropathy Spectrum Disorder (ANSD) presented by normal or near-normal functional capacity of cochlear hair cells and the absent or abnormal functional capability of the auditory nerve. The aim of the present study was the identification of the scientific literature according to the presence of ANSD following oxaliplatin.
Material and Method: A systematic review of the scientific literature in the international databases (PubMed, ScienceDirect, Scopus, Cochrane Library and Google Scholar) was performed from January 1, 2006, to June 15, 2018. The main exclusion criterion was the absence of abstract, the full-text and the English language.
Results: Fifteen (n = 15) articles were identified. Oxaliplatin-related ototoxicity was no presented in six (n = 6) articles while cochlear toxicity was noted in four (n = 4) articles, and cases reports of ototoxicity were included in five (n = 5) articles.
Discussion: Heterogeneity was noted by clinical and in vitro or in vivo studies, case reports, and reviews. Although oxaliplatin induced ototoxicity was supported by the outcomes of most of the studies however the lack of ototoxicity was presented in clinical studies.
Conclusions: Oxaliplatin's action on hair cochlear cells, spiral ganglion, and acoustic nerve fibers has been identified by in vivo or in vitro studies. These results trigger further investigation in the area of oxaliplatin induced ANSD. Moreover, Tympanometry, Otoacoustic Emissions (OAEs), Acoustic Reflexes (ARs), Auditory Brainstem Response (ABR), Gap In Noise (GIN), Pure Tone Audiometry (PTA) and Words In Bubbles (WIB) could evaluate the audiological state of the patient population who received oxaliplatin.
Keywords:
ANSD, Oxaliplatin, Cochlear toxicity, Ototoxicity
